バイオシミラーモノクローナル抗体市場レポート：2022-2032年

Biosimilar Monoclonal Antibodies Market Report 2022-2032

レポート詳細バイオシミラーモノクローナル抗体市場レポート 2022-2032年 :本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
Visiongain ヴィジョンゲイン社	2022年7月25日	GBP4,500 部署ライセンスライセンス・価格情報注文方法はこちら	461	510	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

レポート詳細

バイオシミラーモノクローナル抗体市場レポート 2022-2032年:本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益なものとなるでしょう。また、異業種への進出や新地域での既存事業の拡大を目指す企業にとっても有用なレポートです。

費用対効果の高いバイオシミラーへの需要の高まり
バイオ医薬品の製造において生物学的製剤を利用することは、複雑性を増す。その結果、バイオシミラーは、機能や用途が類似しているにもかかわらず、生物学的製剤の「完全な」複製品とは言えません。がん、関節リウマチ、糖尿病、貧血などは、先発品の生物学的製剤やバイオシミラーの助けを借りて治療される疾患のほんの一例である。バイオシミラー医薬品は、先発医薬品を正確に複製したものであるため、先発医薬品よりもコストが低くなっています。

バイオシミラーモノクローナル抗体市場は、先進的なモノクローナル抗体生産の増加、高齢者人口の増加、癌、腎不全、リウマチ、乾癬、糖尿病などの慢性疾患の高い有病率などが、世界市場の成長に寄与する要因となっています。さらに、特許が切れそうなmAbが増加していることも、今後数年間で市場成長の可能性を高めると思われます。

マーケットリサーチレポートを購入する前に、どのような質問をすべきでしょうか？
- バイオシミラーモノクローナル抗体市場はどのように進化しているのか？
- バイオシミラーモノクローナル抗体市場の推進要因と抑制要因は何か？
- バイオシミラーモノクローナル抗体の各サブマーケット分野は予測期間中にどのように成長し、これらのサブマーケットが2032年にどれだけの売上を占めるのか?
- 2022年から2032年にかけて、各バイオシミラーモノクローナル抗体のサブマーケットの市場シェアはどのように推移するのでしょうか？
- 2022年から2032年にかけて、市場全体の主なドライバーは何でしょうか？
- バイオシミラーモノクローナル抗体の主要市場はマクロ経済のダイナミクスに概ね追随するのか、それとも個々の国内市場が他を凌駕するのか?
- 2032年までに各国市場のシェアはどのように変化し、どの地域が2032年の市場をリードするのでしょうか？
- リーディングプレイヤーは誰か、また予測期間中の見通しは？
- これらの主要企業のバイオシミラーモノクローナル抗体プロジェクトはどのようなものですか？
- 2020年から2032年にかけて、業界はどのように進化していくのか？現在および今後10年間に実施されるバイオシミラーモノクローナル抗体プロジェクトはどのような意味を持つのか？
- バイオシミラーモノクローナル抗体市場をさらに拡大するために、製品の商業化の必要性は高まっているのか？
- バイオシミラーモノクローナル抗体市場はどこへ向かい、どのようにすれば市場の最前線に立つことができるのか？
- 新製品やサービスラインに対する最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

バイオシミラーモノクローナル抗体市場に現在、そして今後10年間、どのような影響を与えるかを知る必要があります。

- 本レポートは461ページにわたり、238の表と272のグラフを掲載しています。
- このレポートでは、業界における主要な収益性の高い分野をハイライトしているため、今すぐターゲットを絞ることができます。
- 世界、地域、国別の売上高と成長率を詳細に分析しています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。

本レポートは、バイオシミラーモノクローナル抗体市場が今後10年間にどのように発展し、COVID-19の景気後退と回復の変動に伴って変化していくかを教えてくれます。この市場は、過去10年間のどの時点よりも、今がより重要なのです。

レポートでは、COVID-19のバリエーションや経済データなど、お客様の市場に特化した独自の情報をお届けしています。

2032年までの予測やその他の分析により、商業的な展望が見えてくる
- 2032年までの収益予測に加え、直近の実績、成長率、市場シェアもご覧いただけます。
- ビジネスの展望や展開など、独自の分析もご覧いただけます。
- 定性的分析（市場力学、促進要因、機会、阻害要因、課題など）、コスト構造、バイオシミラーモノクローナル抗体の価格上昇の影響、最近の開発状況などをご覧いただけます。

本レポートでは、COVID-19が業界と貴社にどのような影響を与えるかについて、データ分析と貴重な洞察を掲載しています。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じています。

報告書の対象セグメント

タイプ別市場セグメント
- 合成化学品
- バイオ医薬品

用途別市場セグメント
- 慢性疾患・自己免疫疾患
- オンコロジー疾患
- その他の用途

化合物別市場セグメント
・ Infliximab
・ Rituximab
・ Abciximab
・ Trastuzumab
・ Adalimumab
・ Bevacizumab

世界市場全体およびセグメントの収益予測に加え、4地域および20の主要国市場の収益予測も掲載しています。

北米
- 米国
- カナダ
- メキシコ

欧州
- ドイツ
- スペイン
- イギリス
- フランス
- イタリア
- その他の欧州

アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋地域

LAMEA
- ブラジル
- トルコ
- サウジアラビア
- 南アフリカ
- UAE
- その他のラテンアメリカ地域

バイオシミラーモノクローナル抗体市場の2022年から2032年までの主要企業のプロファイルと、これらの企業の事業のこのセグメントに焦点を当てたものも含まれています。

主要企業と市場成長の可能性
・ 3SBio Inc.
・ AbbVie Inc. (AbbVie)
・ Amgen Inc.
・ BIOCAD
・ Biocon Limited
・ Boehringer Ingelheim
・ Celltrion Healthcare Co Ltd.
・ Dong-A Socio Holdings
・ Dr. Reddy’s Laboratories Ltd
・ Genor Biopharma Holdings Ltd.
・ Intas Pharmaceuticals Ltd.
・ Novartis AG
・ Pfizer Inc.
・ Reliance Industries Limited
・ Torrent Pharmaceuticals Limited

バイオシミラーモノクローナル抗体市場の世界全体の収益、2022年から2032年まで金額ベースで、2022年に47億4900万米ドルを突破すると、当研究所は算出しています。また、2032年までの間に売上が大きく伸びると予測しています。本調査では、最も大きな可能性を秘めた企業を特定します。彼らの能力、進歩、商業的展望を知ることで、一歩先を行くことができます。

バイオシミラーモノクローナル抗体市場、2022年から2032年までのレポートはどのように役立つのでしょうか？
480ページを超えるレポートでは、要約すると以下のような知識を得ることができます。

- バイオシミラーモノクローナル抗体市場の2032年までの収益予測、タイプ、用途、化合物、企業規模の各予測を世界および地域レベルで掲載 - 産業の展望を見出し、投資と収益に最も有利な場所を見つけることが可能です。

- 4つの地域と20の主要国市場の2032年までの収益予測 - バイオシミラーモノクローナル抗体市場、2022年から2032年までの北米、欧州、アジア太平洋、LAMEAの市場予測をご覧いただけます。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの主要経済圏の市場も予測されています。

- バイオシミラーモノクローナル抗体市場に関わる主要企業15社の企業プロファイルを含む、既存企業および市場参入を目指す企業の展望（2022年から2032年まで）。

定量的・定性的な分析と独自の予測をご覧いただけます。私たちのレポートだけが持つ情報を入手し、貴重なビジネスインテリジェンスを得ることができます。

他にはない情報
私たちの新しいレポートがあれば、知識の遅れを取り戻し、チャンスを逃す可能性が低くなります。私たちの研究が貴社の研究、分析、意思決定にどのように役立つかをご覧ください。Visiongainの研究は、バイオシミラーモノクローナル抗体市場、2022年から2032年、市場をリードする企業のための商業分析を必要とするすべての人のためのものです。データ、トレンド、予測を見つけることができます。

ページTOPに戻る

1 レポートの概要
1.1 バイオシミラーモノクローナル抗体市場の紹介
1.2 世界のバイオシミラーモノクローナル抗体市場の概要
1.3 本レポートの目的とは？
1.4 レポートのスコープとは？
1.5 バイオシミラーモノクローナル抗体市場の定義
1.6 本レポートを読むべき理由
1.7 本レポートが提供するもの
1.8 本分析レポートが回答する主な質問には以下が含まれます。
1.9 本レポートは誰のためのものなのか？
1.10 調査方法
1.10.1 一次調査
1.10.2 セカンダリーリサーチ
1.10.3 市場評価・予測手法
1.11 よくある質問と回答（FAQ）
1.12 関連するVisiongainのレポート
1.13 Visiongainについて

2 エグゼクティブサマリー
2.1 紹介

3 バイオシミラーモノクローナル抗体の産業構造
3.1 市場と技術の背景
3.2 バイオシミラー医薬品のライフサイクル
3.3 バイオシミラー医薬品の開発
3.4 細胞株の開発と選択
3.5 大腸菌細胞
3.6 哺乳類細胞
3.7 バイオシミラー医薬品の製造
3.8 バイオシミラーの前臨床試験とバリデーション
3.9 臨床試験
3.10 規制当局による承認
3.11 ファーマコビジランス／承認後モニタリング

4 グローバル市場のダイナミクス
4.1 市場の推進要因
4.1.1 バイオシミラー。費用対効果の高い医療への道を切り開く
4.1.2 幅広い疾患の治療において、mAbは今後も主要な治療モダリティであり続ける
4.2 市場抑制要因
4.2.1 モノクローナル抗体の複雑さとバイオシミラー製造
4.2.2 バイオシミラー規制経路のいくつかの重要な特徴はまだ確定していない
4.3 グローバル市場における機会
4.3.1 バイオシミラー多国籍企業の売上向上に貢献する現地企業
4.3.2 新興国は有望な成長機会を提供する
4.4 世界市場における課題
4.4.1 医薬品コストの高騰が重要な課題となっている
4.4.2 予測不可能な規制の状況
4.4.3 バイオシミラー企業はインフラに対処する必要がある
4.5 PEST分析
4.5.1 政治的要因
4.5.2 経済的要因
4.5.3 社会的要因
4.5.4 技術的要因

5 世界のバイオシミラーモノクローナル抗体市場分析
5.1 世界市場の展望
5.2 世界市場規模の推計と予測
5.2.1 COVID-19以前の市場シナリオ

6 世界のバイオシミラーモノクローナル抗体市場：地域別
6.1.1 COVID-19前の市場シナリオ
6.1.2 ポストCOVID-19の市場シナリオ（V、W、U、L字回復の分析）

7 世界のバイオシミラーモノクローナル抗体市場：タイプ別
7.1.1 合成化学品
7.1.2 バイオ医薬品
7.1.3 COVID-19前の市場シナリオ
7.1.4 ポストCOVID-19の市場シナリオ（V、W、U、L字回復の分析）

8 世界のバイオシミラーモノクローナル抗体市場：用途別
8.1.1 慢性疾患・自己免疫疾患
8.1.2 オンコロジー
8.1.3 COVID-19前の市場シナリオ
8.1.4 ポストCOVID-19の市場シナリオ（V、W、U、L字型回復分析）

9 世界のバイオシミラーモノクローナル抗体市場化合物別
9.1.1 インフリキシマブ
9.1.2 リツキシマブ（Rituximab
9.1.3 アブシキシマブ
9.1.4 トラスツズマブ
9.1.5 アダリムマブ
9.1.6 ベバシズマブ
9.1.7 COVID-19前の市場シナリオ
9.1.8 ポストCOVID-19の市場シナリオ（V、W、U、L字回復の分析）

10 北米のバイオシミラーモノクローナル抗体市場分析
10.1 北米バイオシミラーモノクローナル抗体市場（金額別）
10.1.1 COVID-19前の市場シナリオ
10.1.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
10.2 北米バイオシミラーモノクローナル抗体国別市場
10.2.1 COVID-19前の市場シナリオ
10.2.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
10.3 米国バイオシミラーモノクローナル抗体市場分析
10.3.1 FDAが糖尿病治療用の交換可能なバイオシミラーインスリン製剤を初承認
10.3.2 COVID-19前の市場シナリオ
10.3.3 ポストCOVID-19市場シナリオ（V、W、U、L字型回復分析）
10.4 カナダバイオシミラーモノクローナル抗体市場分析
10.4.1 ノースウエスト準州がカナダで5番目のバイオシミラー切り替えイニシアチブを実施する管轄区となる
10.4.2 COVID-19とカナダにおけるジェネリック医薬品とバイオシミラー医薬品の供給と流通に関するCGPA/バイオシミラーズ・カナダのステートメント
10.4.3 COVID-19前の市場シナリオ
10.4.4 COVID-19後の市場シナリオ（V、W、U、L字型回復分析）
10.5 メキシコバイオシミラーモノクローナル抗体市場分析
10.5.1 メキシコバイオシミラー、医薬品、医療機器に対する規制当局の承認制度に大きな変化
10.5.2 COVID-19前の市場シナリオ
10.5.3 ポストCOVID-19市場シナリオ（V、W、U、L字型回復分析）
10.6 北米バイオシミラーモノクローナル抗体市場：タイプ別
10.6.1 COVID-19前の市場シナリオ
10.6.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
10.7 北米バイオシミラーモノクローナル抗体市場：用途別
10.7.1 COVID-19前の市場シナリオ
10.7.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
10.8 北米バイオシミラーモノクローナル抗体化合物別市場
10.8.1 COVID-19前の市場シナリオ
10.8.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）

11 欧州のバイオシミラーモノクローナル抗体市場分析
11.1 欧州市場の展望
11.2 欧州バイオシミラーモノクローナル抗体市場（金額ベース）
11.2.1 COVID-19前の市場シナリオ
11.2.2 ポストCOVID-19市場シナリオ（V、W、U、L字型回復分析）
11.3 欧州バイオシミラーモノクローナル抗体国別市場
11.3.1 COVID-19前の市場シナリオ
11.3.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
11.4 ドイツバイオシミラーモノクローナル抗体市場分析
11.4.1 COVID-19前の市場シナリオ
11.4.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
11.5 英国バイオシミラーモノクローナル抗体市場分析
11.5.1 アブゼナとの提携
11.5.2 COVID-19前の市場シナリオ
11.5.3 ポストCOVID-19の市場シナリオ（V、W、U、L字回復の分析）
11.6 フランス・バイオシミラーモノクローナル抗体市場分析
11.6.1 COVID-19前の市場シナリオ
11.6.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
11.7 イタリアバイオシミラーモノクローナル抗体市場分析
11.7.1 COVID-19前の市場シナリオ
11.7.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
11.8 スペインバイオシミラーモノクローナル抗体市場分析
11.8.1 スペインで発売されたベバシズマブ・バイオシミラー
11.8.2 COVID-19前の市場シナリオ
11.8.3 ポストCOVID-19の市場シナリオ（V、W、U、L字型回復分析）
11.9 ヨーロッパ以外のバイオシミラーモノクローナル抗体市場分析
11.9.1 COVID-19前の市場シナリオ
11.9.2 ポストCOVID-19の市場シナリオ（V、W、U、L字回復の分析）
11.10 欧州バイオシミラーモノクローナル抗体のタイプ別市場
11.10.1 COVID-19前の市場シナリオ
11.10.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
11.11 欧州バイオシミラーモノクローナル抗体用途別市場
11.11.1 COVID-19前の市場シナリオ
11.11.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
11.12 欧州バイオシミラーモノクローナル抗体化合物別市場
11.12.1 COVID-19前の市場シナリオ
11.12.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）

12 アジア太平洋地域のバイオシミラーモノクローナル抗体市場分析
12.1 アジア太平洋地域の市場展望
12.2 アジア太平洋地域のバイオシミラーモノクローナル抗体市場（金額別）
12.2.1 COVID-19前の市場シナリオ
12.2.2 ポストCOVID-19市場シナリオ（V、W、U、L字型回復分析）
12.3 アジア太平洋地域のバイオシミラーモノクローナル抗体国別市場
12.3.1 COVID-19前の市場シナリオ
12.3.2 ポストCOVID-19の市場シナリオ（V、W、U、L字回復の分析）
12.4 中国バイオシミラーモノクローナル抗体市場分析
12.4.1 COVID-19前の市場シナリオ
12.4.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
12.5 インド・バイオシミラーモノクローナル抗体市場分析
12.5.1 ロシュの抗体カクテル（カシリビマブとイムデビマブ）がインドで販売開始、シプラ社がインド全土で販売へ
12.5.2 COVID-19前の市場シナリオ
12.5.3 ポストCOVID-19の市場シナリオ（V、W、U、L字回復分析）
12.6 日本バイオシミラーモノクローナル抗体市場分析
12.6.1 日本で発売されたアダリムマブ・バイオシミラー医薬品
12.6.2 COVID-19前の市場シナリオ
12.6.3 ポストCOVID-19の市場シナリオ（V、W、U、L字回復の分析）
12.7 韓国バイオシミラーモノクローナル抗体市場分析
12.7.1 韓国におけるベバシズマブ・バイオシミラーOnbevziの上市
12.7.2 COVID-19前の市場シナリオ
12.7.3 ポストCOVID-19の市場シナリオ（V、W、U、L字型回復分析）
12.8 オーストラリアバイオシミラーモノクローナル抗体市場分析
12.8.1 COVID-19前の市場シナリオ
12.8.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
12.9 その他のアジア太平洋地域のバイオシミラーモノクローナル抗体市場分析
12.9.1 COVID-19前の市場シナリオ
12.9.2 ポストCOVID-19市場シナリオ（V、W、U、L字型回復の分析）
12.10 アジア太平洋地域のバイオシミラーモノクローナル抗体市場：タイプ別
12.10.1 COVID-19前の市場シナリオ
12.10.2 ポストCOVID-19市場シナリオ（V、W、U、L字型回復の分析）
12.11 アジア太平洋地域のバイオシミラーモノクローナル抗体市場：用途別
12.11.1 COVID-19前の市場シナリオ
12.11.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
12.12 アジア太平洋地域のバイオシミラーモノクローナル抗体の化合物別市場
12.12.1 COVID-19前の市場シナリオ
12.12.2 ポストCOVID-19の市場シナリオ（V、W、U、L字回復の分析）

13 LAMEAのバイオシミラーモノクローナル抗体市場分析
13.1 LAMEAの市場展望
13.2 LAMEAバイオシミラーモノクローナル抗体市場（金額別）
13.2.1 COVID-19前の市場シナリオ
13.2.2 ポストCOVID-19市場シナリオ（V、W、U、L字型回復分析）
13.3 LAMEAバイオシミラーモノクローナル抗体国別市場
13.3.1 COVID-19前の市場シナリオ
13.3.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
13.4 LAMEA バイオシミラーモノクローナル抗体のタイプ別市場
13.4.1 COVID-19前の市場シナリオ
13.4.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
13.5 LAMEA バイオシミラーモノクローナル抗体市場：用途別
13.5.1 COVID-19前の市場シナリオ
13.5.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
13.6 LAMEA バイオシミラーモノクローナル抗体市場：化合物別
13.6.1 COVID-19前の市場シナリオ
13.6.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
13.7 ブラジルバイオシミラーモノクローナル抗体市場分析
13.7.1 COVID-19前の市場シナリオ
13.7.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
13.8 南アフリカのバイオシミラーモノクローナル抗体市場分析
13.8.1 COVID-19前の市場シナリオ
13.8.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
13.9 サウジアラビアのバイオシミラーモノクローナル抗体市場分析
13.9.1 COVID-19前の市場シナリオ
13.9.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
13.10 トルコのバイオシミラーモノクローナル抗体市場分析
13.10.1 COVID-19前の市場シナリオ
13.10.2 ポストCOVID-19の市場シナリオ（V、W、U、L字回復の分析）
13.11 UAEバイオシミラーモノクローナル抗体市場分析
13.11.1 COVID-19前の市場シナリオ
13.11.2 ポストCOVID-19市場シナリオ（V、W、U、L字回復分析）
13.12 その他のLAMEAのバイオシミラーモノクローナル抗体の市場分析
13.12.1 COVID-19前の市場シナリオ
13.12.2 ポストCOVID-19市場シナリオ（V、W、U、L字型回復の分析）

14 主要企業のプロフィール
14.1 ファイザー株式会社
14.1.1 企業スナップショット
14.1.2 会社概要
14.1.3 会社の財務状況
14.1.4 会社の製品ベンチマーク
14.1.5 会社の最近の動向
14.2 ノバルティスAG
14.2.1 会社概要
14.2.2 会社概要
14.2.3 財務プロファイル
14.2.4 製品ベンチマーク
14.2.5 会社の最近の動向
14.3 ベーリンガーインゲルハイムGmbH
14.3.1 会社概要
14.3.2 会社概要
14.3.3 財務概要
14.3.4 会社の製品ベンチマーク
14.3.5 会社の最近の動向
14.4 インタス・ファーマシューティカルズ・リミテッド
14.4.1 会社概要
14.4.2 会社概要
14.4.3 会社の製品ベンチマーク
14.5 アムジェン
14.5.1 企業スナップショット
14.5.2 会社概要
14.5.3 財務プロファイル
14.5.4 会社の製品ベンチマーク
14.5.5 会社の最近の動向
14.6 バイオコン
14.6.1 会社概要
14.6.2 会社概要
14.6.3 財務プロフィール
14.6.4 会社の製品ベンチマーク
14.6.5 会社の最近の開発
14.7 セルトリオン・ヘルスケア
14.7.1 会社概要
14.7.2 会社概要
14.7.3 財務プロファイル
14.7.4 会社の製品ベンチマーク
14.7.5 会社の最近の動向
14.8 東亜ソシオホールディングス
14.8.1 会社概要
14.8.2 会社概要
14.8.3 財務概要
14.8.4 会社の製品ベンチマーク
14.8.5 会社の最近の動向
14.9 ドクター・レディーズ・ラボラトリーズ・リミテッド
14.9.1 会社概要
14.9.2 会社概要
14.9.3 財務プロフィール
14.9.4 製品ベンチマーク
14.9.5 会社の最近の動向
14.10 3SBio
14.10.1 会社概要
14.10.2 会社概要
14.10.3 財務概要
14.10.4 会社の製品ベンチマーク
14.10.5 会社の最近の開発状況
14.11 アラガン(アッヴィー社)
14.11.1 会社概要
14.11.2 会社概要
14.11.3 財務プロファイル
14.11.4 会社の製品ベンチマーク
14.11.5 会社の最近の開発
14.12 ジェノア・バイオファーマ
14.12.1 会社概要
14.12.2 会社概要
14.12.3 当社の製品ベンチマーク
14.12.4 会社の最近の動向
14.13 リライアンス・ライフサイエンス
14.13.1 企業スナップショット
14.13.2 会社概要
14.13.3 当社製品のベンチマーキング
14.13.4 会社の最近の動向
14.14 トレント・ファーマシューティカルズ
14.14.1 企業スナップショット
14.14.2 会社概要
14.14.3 財務プロファイル
14.14.4 当社の製品ベンチマーク
14.14.5 会社の最近の動き
14.15 BIOCAD
14.15.1 会社概要
14.15.2 会社概要
14.15.3 ベンチマーキング
14.15.4 会社の最近の動向

15 結論と提言
15.1 結論の結論
15.2 市場関係者への提言

表の一覧
Table 1. Global Biosimilar Monoclonal Antibodies Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 2. Global Biosimilar Monoclonal Antibodies Market Snapshot, 2022 & 2032 (US$million, CAGR %)
Table 3. List of Biosimilars Produced in E. Coli
Table 4. List of Biosimilars Produced in Mammalian Cells
Table 5. Key Differences in Approval Pathways for Biosimilars, European Union (EU) vs. United Sates (U.S.)
Table 6. US Approved Biosimilars
Table 7. Biosimilar Monoclonal Antibodies Swot Analysis
Table 8. Global Biosimilar Monoclonal Antibodies Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 9. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 10. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 11. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 12. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 13. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 14. 50 Biopharmaceuticals Products
Table 15. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 16. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 17. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 18. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 19. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 20. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 21. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 22. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 23. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 24. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 25. Biosimilar Active Substance Reference Product Company
Table 26. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 27. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 28. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 29. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 30. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 31. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 32. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 33. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 34. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 35. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 36. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 37. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 38. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 39. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 40. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 41. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 42. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 43. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 44. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 45. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 46. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 47. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 48. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 49. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 50. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 51. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 52. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 53. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 54. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 55. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 56. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 57. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 58. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 59. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 60. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 61. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 62. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 63. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 64. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 65. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 66. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 67. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 68. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 69. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 70. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 71. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 72. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 73. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 74. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 75. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 76. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 77. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 78. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 79. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 80. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 81. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 82. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 83. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 84. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 85. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 86. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 87. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 88. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 89. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 90. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 91. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 92. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 93. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 94. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 95. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 96. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 97. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 98. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 99. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 100. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 101. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 102. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 103. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 104. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 105. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 106. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 107. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 108. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 109. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 110. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 111. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 112. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 113. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 114. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 115. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 116. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 117. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 118. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 119. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 120. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 121. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 122. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 123. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 124. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 125. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 126. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 127. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 128. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 129. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 130. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 131. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 132. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 133. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 134. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 135. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 136. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 137. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 138. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 139. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 140. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 141. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 142. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 143. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 144. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 145. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 146. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 147. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 148. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 149. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 150. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 151. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 152. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 153. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 154. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 155. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 156. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 157. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 158. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 159. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 160. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 161. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 162. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 163. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 164. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 165. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 166. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 167. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 168. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 169. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 170. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 171. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 172. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 173. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 174. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 175. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 176. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 177. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 178. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 179. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 180. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 181. LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 182. LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 183. LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 184. LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 185. LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 186. LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 187. LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 188. LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 189. LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 190. LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 191. LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 192. LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 193. LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 194. LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 195. LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 196. LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 197. LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 198. LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 199. LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 200. LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 201. LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 202. LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 203. LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 204. LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 205. LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 206. Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 207. Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 208. Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 209. Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 210. Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 211. South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 212. South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 213. South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 214. South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 215. South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 216. Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 217. Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 218. Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 219. Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 220. Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 221. Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 222. Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 223. Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 224. Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 225. Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 226. UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 227. UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 228. UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 229. UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 230. UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 231. Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 232. Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 233. Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 234. Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 235. Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 236. Business Strategy: Acquisition, Expansion and Investment
Table 237. Business Strategy: Agreement, Contracts and Establishment
Table 238. Business Strategy: Partnership, Collaboration and Joint Venture

図の一覧
Figure 1 Global Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR(%))
Figure 2 Global Biosimilar Monoclonal Antibodies Market Segmentation
Figure 3 Current Trends in the Global Market
Figure 4 Biosimilar Monoclonal Antibodies PEST Analysis
Figure 5 Biosimilar Monoclonal Antibodies Porter’s Five Forces.
Figure 6 Global Biosimilar Monoclonal Antibodies Market Forecast, 2022-2032 (USD Mn, AGR (%))
Figure 7 Global Biosimilar Monoclonal Antibodies Market Share Forecast by Region, 2022, 2027, 2032 (%)
Figure 8 Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%)}
Figure 9 Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%))
Figure 10 Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%))
Figure 11 Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%))
Figure 12 Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%))
Figure 13 Global Biosimilar Monoclonal Antibodies Market Share Forecast by Type, 2022, 2027, 2032 (%)
Figure 14 Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 15 Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 16 Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 17 Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 18 Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 19 Global Biosimilar Monoclonal Antibodies Market Share Forecast by Application, 2022, 2027, 2032 (%)
Figure 20 Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 21 Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 22 Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 23 Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 24 Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 25 Global Biosimilar Monoclonal Antibodies Market Share Forecast by Compound, 2022, 2027, 2032 (%)
Figure 26 Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 27 Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 28 Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 29 Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 30 Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 31 North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 32 North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 33 North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 34 North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 35 North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 36 North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 37 North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 38 North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 39 North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 40 North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 41 US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 42 US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 43 US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 44 US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 45 US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 46 Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 47 Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 48 Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 49 Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 50 Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 51 Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 52 Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 53 Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 54 Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 55 Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 56 North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 57 North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 58 North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 59 North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 60 North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 61 North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 62 North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 63 North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 64 North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 65 North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 66 North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 67 North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 68 North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 69 North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 70 North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 71 Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 72 Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 73 Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 74 Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 75 Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 76 Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 77 Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 78 Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 79 Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 80 Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 81 Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 82 Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 83 Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 84 Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 85 Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 86 UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 87 UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 88 UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 89 UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 90 UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 91 France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 92 France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 93 France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 94 France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 95 France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 96 Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 97 Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 98 Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 99 Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 100 Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 101 Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 102 Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 103 Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 104 Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 105 Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 106 Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 107 Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 108 Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 109 Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 110 Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 111 Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 112 Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 113 Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 114 Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 115 Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 116 Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 117 Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 118 Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 119 Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 120 Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 121 Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 122 Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 123 Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 124 Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 125 Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 126 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 127 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 128 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 129 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 130 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 131 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 132 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 133 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 134 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 135 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 136 China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 137 China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 138 China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 139 China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 140 China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 141 India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 142 India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 143 India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 144 India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 145 India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 146 Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 147 Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 148 Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 149 Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 150 Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 151 South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 152 South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 153 South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 154 South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 155 South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 156 Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 157 Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 158 Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 159 Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 160 Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 161 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 162 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 163 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 164 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 165 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 166 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 167 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 168 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 169 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 170 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 171 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 172 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 173 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 174 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 175 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 176 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 177 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 178 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 179 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 180 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 181 LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 182 LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 183 LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 184 LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 185 LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 186 LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 187 LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 188 LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 189 LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 190 LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 191 LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 192 LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 193 LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 194 LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 195 LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 196 LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 197 LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 198 LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 199 LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 200 LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 201 LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 202 LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 203 LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 204 LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 205 LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 206 Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 207 Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 208 Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 209 Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 210 Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 211 South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 212 South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 213 South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 214 South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 215 South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 216 Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 217 Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 218 Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 219 Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 220 Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 221 Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 222 Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 223 Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 224 Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 225 Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 226 UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 227 UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 228 UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 229 UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 230 UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 231 Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 232 Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 233 Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 234 Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 235 Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 234 Pfizer Inc.: Company Operating Income 2017-2021 (US$Mn, AGR %)
Figure 235 Pfizer Inc.: Company Net Income 2017-2021 (US$Mn, AGR %)
Figure 236 Pfizer Inc.: Company EBITDA 2017-2021 (US$Mn, AGR %)
Figure 237 Novartis AG: Company Revenue 2017-2021 (US$Mn, AGR %)
Figure 238 Novartis AG: Company Operating Income 2017-2021 (US$Mn, AGR %)
Figure 239 Novartis AG : Company Net Income 2017-2021 (US$Mn, AGR %)
Figure 240 Novartis AG : Company EBITDA 2017-2021 (US$Mn, AGR %)
Figure 241 Boehringer Ingelheim GmbH: Company Revenue 2017-2021 (US$Mn, AGR %)
Figure 242 Amgen Inc: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 243 Amgen Inc: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 244 Amgen Inc: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 245 Biocon Limited: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 246 Biocon Limited: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 247 Biocon Limited: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 248 Biocon Limited: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 249 Celltrion Healthcare Co Ltd: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 250 Celltrion Healthcare Co Ltd: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 251 Celltrion Healthcare Co Ltd: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 252 Celltrion Healthcare Co Ltd: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 253 Dong-A Socio Holdings Co., Ltd: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 254 Dong-A Socio Holdings Co., Ltd: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 255 Dong-A Socio Holdings Co., Ltd: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 256 Dong-A Socio Holdings Co., Ltd: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 257 Dr. Reddy’s Laboratories Limited: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 258 Dr. Reddy’s Laboratories Limited: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 259 Dr. Reddy’s Laboratories Limited: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 260 Dr. Reddy’s Laboratories Limited: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 261 3SBio Inc: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 262 3SBio Inc: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 263 3SBio Inc: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 264 3SBio Inc: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 265 AbbVie Inc: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 266 AbbVie Inc: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 267 AbbVie Inc: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 268 AbbVie Inc: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 269 Torrent Pharmaceuticals Limited: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 270 Torrent Pharmaceuticals Limited: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 271 Torrent Pharmaceuticals Limited: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 272 Torrent Pharmaceuticals Limited: Company EBITDA 2017-2021(US$Mn, AGR %)

ページTOPに戻る

Table of Contents

Summary

この調査レポートは世界のバイオシミラーモノクローナル抗体市場を調査し、タイプ別、用途別、化合物別、地域別に2022年から2032年までの予測結果を掲載しています。また関連企業情報を提供しています。

主な掲載内容（目次より抜粋）

レポート概要
エグゼクティブサマリー
バイオシミラーモノクローナル抗体の業界構造
世界市場のダイナミックス
世界のバイオシミラーモノクローナル抗体市場分析
世界のバイオシミラーモノクローナル抗体市場：地域別
世界のバイオシミラーモノクローナル抗体市場：タイプ別
世界のバイオシミラーモノクローナル抗体市場：用途別
世界のバイオシミラーモノクローナル抗体市場：化合物別
北米のバイオシミラーモノクローナル抗体市場分析
欧州のバイオシミラーモノクローナル抗体市場分析
アジア太平洋地域のバイオシミラーモノクローナル抗体市場分析
LAMEAのバイオシミラーモノクローナル抗体市場分析
主要企業のプロフィール

Report Details

The Biosimilar Monoclonal Antibodies Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Demand for Cost-Effective Biosimilars
The utilization of biological agents in the manufacturing of biopharma products increases complexity. As a result, biosimilars are not “exact” replicas of their biological counterparts despite being similar in function and intended use. Cancer, rheumatoid arthritis, diabetes, and anemia are just a few of the conditions that are treated with the help of branded biologics and biosimilars. The cost of biosimilar pharmaceuticals is lower than that of branded drugs because they are exact replicas of their branded counterparts.

The rise in advanced monoclonal antibody production, rising geriatric population, and high prevalence of chronic diseases like cancer, renal failure, rheumatoid, psoriasis, diabetes, and others are all factors contributing to the growth of the global biosimilar monoclonal antibodies market. Additionally, the increasing number of mAbs whose patents are about to expire will probably increase market growth potential in the years to come.

What Questions Should You Ask before Buying a Market Research Report?
• How is the biosimilar monoclonal antibodies market evolving?
• What is driving and restraining the biosimilar monoclonal antibodies market?
• How will each biosimilar monoclonal antibodies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each biosimilar monoclonal antibodies submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading biosimilar monoclonal antibodies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the biosimilar monoclonal antibodies projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2032? What are the implications of biosimilar monoclonal antibodies projects taking place now and over the next 10 years?
• Is there a greater need for product commercialization to further scale the biosimilar monoclonal antibodies market?
• Where is the biosimilar monoclonal antibodies market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the biosimilar monoclonal antibodies market today, and over the next 10 years:
• Our 461-page report provides 238 tables and 272 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the biosimilar monoclonal antibodies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

The report delivers exclusive COVID-19 variations and economic data specific to your market.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising biosimilar monoclonal antibodies prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Market Segment by Type
• Synthetic Chemicals
• Biopharmaceuticals

Market Segment by Application
• Chronic & Autoimmune Diseases
• Oncology Diseases
• Other Applications

Market Segment by Compound
• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America
• U.S.
• Canada
• Mexico

Europe
• Germany
• Spain
• United Kingdom
• France
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

LAMEA
• Brazil
• Turkey
• Saudi Arabia
• South Africa
• UAE
• Rest of Latin America

The report also includes profiles and for some of the leading companies in the Biosimilar Monoclonal Antibodies Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• 3SBio Inc.
• AbbVie Inc. (AbbVie)
• Amgen Inc.
• BIOCAD
• Biocon Limited
• Boehringer Ingelheim
• Celltrion Healthcare Co Ltd.
• Dong-A Socio Holdings
• Dr. Reddy’s Laboratories Ltd
• Genor Biopharma Holdings Ltd.
• Intas Pharmaceuticals Ltd.
• Novartis AG
• Pfizer Inc.
• Reliance Industries Limited
• Torrent Pharmaceuticals Limited

Overall world revenue for Biosimilar Monoclonal Antibodies Market, 2022 to 2032 in terms of value the market will surpass US$4,749 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biosimilar Monoclonal Antibodies Market, 2022 to 2032 report help you?
In summary, our 480+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Biosimilar Monoclonal Antibodies Market, 2022 to 2032 Market, with forecasts for type, application, compound and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for four regional and 20 key national markets – See forecasts for the Biosimilar Monoclonal Antibodies Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 15 of the major companies involved in the Biosimilar Monoclonal Antibodies Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Biosimilar Monoclonal Antibodies Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Introduction to Biosimilar Monoclonal Antibodies Market
1.2 Global Biosimilar Monoclonal Antibodies Market Overview
1.3 What are the Objectives of this Report?
1.4 What is the Scope of the Report?
1.5 Biosimilar Monoclonal Antibodies Market Definition
1.6 Why You Should Read This Report
1.7 What This Report Delivers
1.8 Key Questions Answered By This Analytical Report Include:
1.9 Who is This Report for?
1.10 Research Methodology
1.10.1 Primary Research
1.10.2 Secondary Research
1.10.3 Market Evaluation & Forecasting Methodology
1.11 Frequently Asked Questions (FAQs)
1.12 Associated Visiongain Reports
1.13 About Visiongain

2 Executive Summary
2.1 Introduction

3 Biosimilar Monoclonal Antibodies Industry Structure
3.1 Market and Technology Background
3.2 Lifecycle of a Biosimilar Drug
3.3 Development of a Biosimilar
3.4 Cell Line Development and Selection
3.5 E. coli Cells
3.6 Mammalian Cells
3.7 Manufacturing of a Biosimilar
3.8 Preclinical Studies and Validation of a Biosimilar
3.9 Clinical Trials
3.10 Approval by Regulatory Agencies
3.11 Pharmacovigilance/Post-Approval Monitoring

4 Global Market Dynamics
4.1 Market Driving Factors
4.1.1 Biosimilars: Leading the Way to Cost Effective Healthcare
4.1.2 mAbs Will Continue to be a Dominant Therapeutic Modality for Treatment of a Broad Range of Diseases
4.2 Market Restraining Factors
4.2.1 Monoclonal Antibody Complexity and Biosimilar Manufacturing
4.2.2 Several Critical Features of Biosimilar Regulatory Pathway is Yet to be Finalized
4.3 Opportunities in the Global Market
4.3.1 Local Companies Can Help Multinational Biosimilars Companies Improve Sales
4.3.2 Emerging Economies to Offer Lucrative Growth Opportunities
4.4 Challenges in the Global Market
4.4.1 High Cost of Pharmaceuticals Has Become a Key Issue
4.4.2 Unpredictable Regulatory Landscape
4.4.3 Biosimilars Companies Must Address Infrastructure
4.5 PEST Analysis
4.5.1 Political Factors
4.5.2 Economic Factors
4.5.3 Social Factors
4.5.4 Technology Factors

5 Global Biosimilar Monoclonal Antibodies Market Analysis
5.1 Global Market Outlook
5.2 Global Market Size Estimation and Forecast
5.2.1 Pre-COVID-19 Market Scenario

6 Global Biosimilar Monoclonal Antibodies Market by Region
6.1.1 Pre-COVID-19 Market Scenario
6.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

7 Global Biosimilar Monoclonal Antibodies Market by Type
7.1.1 Synthetic Chemicals
7.1.2 Biopharmaceuticals
7.1.3 Pre-COVID-19 Market Scenario
7.1.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

8 Global Biosimilar Monoclonal Antibodies Market by Application
8.1.1 Chronic & Autoimmune Diseases
8.1.2 Oncology
8.1.3 Pre-COVID-19 Market Scenario
8.1.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

9 Global Biosimilar Monoclonal Antibodies Market by Compound
9.1.1 Infliximab
9.1.2 Rituximab
9.1.3 Abciximab
9.1.4 Trastuzumab
9.1.5 Adalimumab
9.1.6 Bevacizumab
9.1.7 Pre-COVID-19 Market Scenario
9.1.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

10 North America Biosimilar Monoclonal Antibodies Market Analysis
10.1 North America Biosimilar Monoclonal Antibodies Market by Value
10.1.1 Pre-COVID-19 Market Scenario
10.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.2 North America Biosimilar Monoclonal Antibodies Market by Country
10.2.1 Pre-COVID-19 Market Scenario
10.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.3 U.S. Biosimilar Monoclonal Antibodies Market Analysis
10.3.1 FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes
10.3.2 Pre-COVID-19 Market Scenario
10.3.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.4 Canada Biosimilar Monoclonal Antibodies Market Analysis
10.4.1 Northwest Territories Becomes Fifth Jurisdiction in Canada to Implement Biosimilar Switching Initiative
10.4.2 CGPA / Biosimilars Canada Statement on COVID-19 and the Supply and Distribution of Generic and Biosimilar Prescription Medicines in Canada
10.4.3 Pre-COVID-19 Market Scenario
10.4.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.5 Mexico Biosimilar Monoclonal Antibodies Market Analysis
10.5.1 Mexico: Major Change To The Regulatory Approval System For Biosimilars, Medicines And Medical Devices
10.5.2 Pre-COVID-19 Market Scenario
10.5.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.6 North America Biosimilar Monoclonal Antibodies Market by Type
10.6.1 Pre-COVID-19 Market Scenario
10.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.7 North America Biosimilar Monoclonal Antibodies Market by Application
10.7.1 Pre-COVID-19 Market Scenario
10.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.8 North America Biosimilar Monoclonal Antibodies Market by Compound
10.8.1 Pre-COVID-19 Market Scenario
10.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

11 Europe Biosimilar Monoclonal Antibodies Market Analysis
11.1 Europe Market Outlook
11.2 Europe Biosimilar Monoclonal Antibodies Market by Value
11.2.1 Pre-COVID-19 Market Scenario
11.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.3 Europe Biosimilar Monoclonal Antibodies Market by Country
11.3.1 Pre-COVID-19 Market Scenario
11.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.4 Germany Biosimilar Monoclonal Antibodies Market Analysis
11.4.1 Pre-COVID-19 Market Scenario
11.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.5 UK Biosimilar Monoclonal Antibodies Market Analysis
11.5.1 Abzena Collaboration
11.5.2 Pre-COVID-19 Market Scenario
11.5.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.6 France Biosimilar Monoclonal Antibodies Market Analysis
11.6.1 Pre-COVID-19 Market Scenario
11.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.7 Italy Biosimilar Monoclonal Antibodies Market Analysis
11.7.1 Pre-COVID-19 Market Scenario
11.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.8 Spain Biosimilar Monoclonal Antibodies Market Analysis
11.8.1 Bevacizumab Biosimilars Launched in Spain
11.8.2 Pre-COVID-19 Market Scenario
11.8.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.9 Rest of Europe Biosimilar Monoclonal Antibodies Market Analysis
11.9.1 Pre-COVID-19 Market Scenario
11.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.10 Europe Biosimilar Monoclonal Antibodies Market by Type
11.10.1 Pre-COVID-19 Market Scenario
11.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.11 Europe Biosimilar Monoclonal Antibodies Market by Application
11.11.1 Pre-COVID-19 Market Scenario
11.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.12 Europe Biosimilar Monoclonal Antibodies Market by Compound
11.12.1 Pre-COVID-19 Market Scenario
11.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

12 Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis
12.1 Asia-Pacific Market Outlook
12.2 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value
12.2.1 Pre-COVID-19 Market Scenario
12.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.3 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country
12.3.1 Pre-COVID-19 Market Scenarios
12.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.4 China Biosimilar Monoclonal Antibodies Market Analysis
12.4.1 Pre-COVID-19 Market Scenario
12.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.5 India Biosimilar Monoclonal Antibodies Market Analysis
12.5.1 Roche’s Antibody Cocktail (Casirivimab and Imdevimab) Is Now Available In India, Cipla To Market It Pan-India
12.5.2 Pre-COVID-19 Market Scenario
12.5.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.6 Japan Biosimilar Monoclonal Antibodies Market Analysis
12.6.1 Adalimumab Biosimilar Launched in Japan
12.6.2 Pre-COVID-19 Market Scenario
12.6.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.7 South Korea Biosimilar Monoclonal Antibodies Market Analysis
12.7.1 Launch Of Bevacizumab Biosimilar Onbevzi in Korea
12.7.2 Pre-COVID-19 Market Scenario
12.7.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.8 Australia Biosimilar Monoclonal Antibodies Market Analysis
12.8.1 Pre-COVID-19 Market Scenario
12.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.9 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis
12.9.1 Pre-COVID-19 Market Scenario
12.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.10 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type
12.10.1 Pre-COVID-19 Market Scenario
12.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.11 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application
12.11.1 Pre-COVID-19 Market Scenario
12.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.12 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound
12.12.1 Pre-COVID-19 Market Scenario
12.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

13 LAMEA Biosimilar Monoclonal Antibodies Market Analysis
13.1 LAMEA Market Outlook
13.2 LAMEA Biosimilar Monoclonal Antibodies Market by Value
13.2.1 Pre-COVID-19 Market Scenario
13.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.3 LAMEA Biosimilar Monoclonal Antibodies Market by Country
13.3.1 Pre-COVID-19 Market Scenario
13.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.4 LAMEA Biosimilar Monoclonal Antibodies Market by Type
13.4.1 Pre-COVID-19 Market Scenario
13.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.5 LAMEA Biosimilar Monoclonal Antibodies Market by Application
13.5.1 Pre-COVID-19 Market Scenario
13.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.6 LAMEA Biosimilar Monoclonal Antibodies Market by Compound
13.6.1 Pre-COVID-19 Market Scenario
13.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.7 Brazil Biosimilar Monoclonal Antibodies Market Analysis
13.7.1 Pre-COVID-19 Market Scenario
13.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.8 South Africa Biosimilar Monoclonal Antibodies Market Analysis
13.8.1 Pre-COVID-19 Market Scenario
13.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.9 Saudi Arabia Biosimilar Monoclonal Antibodies Market Analysis
13.9.1 Pre-COVID-19 Market Scenario
13.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.10 Turkey Biosimilar Monoclonal Antibodies Market Analysis
13.10.1 Pre-COVID-19 Market Scenario
13.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.11 UAE Biosimilar Monoclonal Antibodies Market Analysis
13.11.1 Pre-COVID-19 Market Scenario
13.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.12 Rest of LAMEA Biosimilar Monoclonal Antibodies Market Analysis
13.12.1 Pre-COVID-19 Market Scenario
13.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

14 Company Profiles
14.1 Pfizer Inc.
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Company Financial Profile
14.1.4 Company Product Benchmarking
14.1.5 Company Recent Developments
14.2 Novartis AG
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Company Financial Profile
14.2.4 Company Product Benchmarking
14.2.5 Company Recent Developments
14.3 Boehringer Ingelheim GmbH
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Company Financial Profile
14.3.4 Company Product Benchmarking
14.3.5 Company Recent Developments
14.4 Intas Pharmaceuticals Ltd.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Company Product Benchmarking
14.5 Amgen
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Company Financial Profile
14.5.4 Company Product Benchmarking
14.5.5 Company Recent Developments
14.6 Biocon
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Company Financial Profile
14.6.4 Company Product Benchmarking
14.6.5 Company Recent Developments
14.7 Celltrion Healthcare Co. Ltd
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Company Financial Profile
14.7.4 Company Product Benchmarking
14.7.5 Company Recent Developments
14.8 Dong-A Socio Holdings
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Company Financial Profile
14.8.4 Company Product Benchmarking
14.8.5 Company Recent Developments
14.9 Dr. Reddy’s Laboratories Ltd
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Company Financial Profile
14.9.4 Company Product Benchmarking
14.9.5 Company Recent Developments
14.10 3SBio
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Company Financial Profile
14.10.4 Company Product Benchmarking
14.10.5 Company Recent Developments
14.11 Allergan(AbbVie Inc.)
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Company Financial Profile
14.11.4 Company Product Benchmarking
14.11.5 Company Recent Developments
14.12 Genor BioPharma Co. Ltd.
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Company Product Benchmarking
14.12.4 Company Recent Developments
14.13 Reliance Life Sciences
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Company Product Benchmarking
14.13.4 Company Recent Developments
14.14 Torrent Pharmaceuticals
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Company Financial Profile
14.14.4 Company Product Benchmarking
14.14.5 Company Recent Developments
14.15 BIOCAD
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Company Product Benchmarking
14.15.4 Company Recent Developments

15 Conclusion and Recommendations
15.1 Conclusion Summary
15.2 Recommendations for Market Players

List of Tables
Table 1. Global Biosimilar Monoclonal Antibodies Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 2. Global Biosimilar Monoclonal Antibodies Market Snapshot, 2022 & 2032 (US$million, CAGR %)
Table 3. List of Biosimilars Produced in E. Coli
Table 4. List of Biosimilars Produced in Mammalian Cells
Table 5. Key Differences in Approval Pathways for Biosimilars, European Union (EU) vs. United Sates (U.S.)
Table 6. US Approved Biosimilars
Table 7. Biosimilar Monoclonal Antibodies Swot Analysis
Table 8. Global Biosimilar Monoclonal Antibodies Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 9. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 10. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 11. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 12. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 13. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 14. 50 Biopharmaceuticals Products
Table 15. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 16. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 17. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 18. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 19. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 20. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 21. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 22. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 23. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 24. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 25. Biosimilar Active Substance Reference Product Company
Table 26. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 27. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 28. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 29. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 30. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 31. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 32. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 33. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 34. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 35. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 36. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 37. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 38. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 39. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 40. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 41. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 42. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 43. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 44. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 45. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 46. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 47. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 48. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 49. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 50. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 51. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 52. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 53. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 54. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 55. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 56. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 57. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 58. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 59. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 60. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 61. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 62. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 63. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 64. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 65. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 66. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 67. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 68. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 69. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 70. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 71. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 72. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 73. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 74. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 75. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 76. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 77. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 78. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 79. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 80. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 81. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 82. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 83. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 84. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 85. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 86. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 87. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 88. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 89. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 90. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 91. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 92. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 93. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 94. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 95. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 96. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 97. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 98. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 99. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 100. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 101. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 102. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 103. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 104. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 105. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 106. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 107. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 108. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 109. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 110. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 111. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 112. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 113. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 114. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 115. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 116. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 117. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 118. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 119. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 120. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 121. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 122. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 123. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 124. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 125. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 126. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 127. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 128. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 129. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 130. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 131. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 132. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 133. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 134. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 135. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 136. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 137. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 138. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 139. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 140. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 141. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 142. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 143. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 144. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 145. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 146. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 147. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 148. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 149. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 150. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 151. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 152. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 153. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 154. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 155. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 156. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 157. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 158. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 159. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 160. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 161. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 162. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 163. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 164. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 165. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 166. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 167. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 168. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 169. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 170. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 171. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 172. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 173. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 174. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 175. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 176. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 177. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 178. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 179. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 180. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 181. LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 182. LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 183. LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 184. LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 185. LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 186. LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 187. LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 188. LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 189. LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 190. LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 191. LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 192. LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 193. LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 194. LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 195. LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 196. LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 197. LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 198. LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 199. LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 200. LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 201. LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 202. LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 203. LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 204. LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 205. LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 206. Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 207. Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 208. Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 209. Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 210. Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 211. South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 212. South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 213. South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 214. South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 215. South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 216. Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 217. Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 218. Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 219. Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 220. Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 221. Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 222. Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 223. Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 224. Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 225. Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 226. UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 227. UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 228. UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 229. UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 230. UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 231. Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 232. Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 233. Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 234. Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 235. Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 236. Business Strategy: Acquisition, Expansion and Investment
Table 237. Business Strategy: Agreement, Contracts and Establishment
Table 238. Business Strategy: Partnership, Collaboration and Joint Venture

List of Figures
Figure 1 Global Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR(%))
Figure 2 Global Biosimilar Monoclonal Antibodies Market Segmentation
Figure 3 Current Trends in the Global Market
Figure 4 Biosimilar Monoclonal Antibodies PEST Analysis
Figure 5 Biosimilar Monoclonal Antibodies Porter’s Five Forces.
Figure 6 Global Biosimilar Monoclonal Antibodies Market Forecast, 2022-2032 (USD Mn, AGR (%))
Figure 7 Global Biosimilar Monoclonal Antibodies Market Share Forecast by Region, 2022, 2027, 2032 (%)
Figure 8 Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%)}
Figure 9 Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%))
Figure 10 Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%))
Figure 11 Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%))
Figure 12 Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%))
Figure 13 Global Biosimilar Monoclonal Antibodies Market Share Forecast by Type, 2022, 2027, 2032 (%)
Figure 14 Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 15 Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 16 Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 17 Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 18 Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 19 Global Biosimilar Monoclonal Antibodies Market Share Forecast by Application, 2022, 2027, 2032 (%)
Figure 20 Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 21 Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 22 Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 23 Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 24 Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 25 Global Biosimilar Monoclonal Antibodies Market Share Forecast by Compound, 2022, 2027, 2032 (%)
Figure 26 Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 27 Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 28 Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 29 Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 30 Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 31 North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 32 North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 33 North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 34 North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 35 North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 36 North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 37 North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 38 North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 39 North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 40 North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 41 US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 42 US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 43 US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 44 US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 45 US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 46 Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 47 Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 48 Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 49 Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 50 Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 51 Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 52 Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 53 Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 54 Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 55 Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 56 North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 57 North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 58 North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 59 North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 60 North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 61 North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 62 North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 63 North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 64 North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 65 North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 66 North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 67 North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 68 North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 69 North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 70 North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 71 Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 72 Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 73 Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 74 Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 75 Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 76 Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 77 Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 78 Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 79 Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 80 Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 81 Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 82 Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 83 Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 84 Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 85 Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 86 UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 87 UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 88 UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 89 UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 90 UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 91 France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 92 France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 93 France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 94 France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 95 France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 96 Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 97 Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 98 Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 99 Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 100 Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 101 Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 102 Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 103 Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 104 Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 105 Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 106 Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 107 Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 108 Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 109 Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 110 Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 111 Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 112 Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 113 Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 114 Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 115 Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 116 Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 117 Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 118 Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 119 Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 120 Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 121 Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 122 Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 123 Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 124 Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 125 Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 126 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 127 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 128 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 129 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 130 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 131 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 132 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 133 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 134 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 135 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 136 China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 137 China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 138 China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 139 China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 140 China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 141 India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 142 India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 143 India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 144 India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 145 India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 146 Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 147 Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 148 Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 149 Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 150 Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 151 South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 152 South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 153 South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 154 South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 155 South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 156 Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 157 Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 158 Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 159 Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 160 Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 161 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 162 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 163 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 164 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 165 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 166 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 167 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 168 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 169 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 170 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 171 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 172 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 173 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 174 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 175 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 176 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 177 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 178 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 179 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 180 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 181 LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 182 LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 183 LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 184 LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 185 LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 186 LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 187 LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 188 LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 189 LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 190 LAMEA Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 191 LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 192 LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 193 LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 194 LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 195 LAMEA Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%))
Figure 196 LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 197 LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 198 LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 199 LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 200 LAMEA Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%))
Figure 201 LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 202 LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 203 LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 204 LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 205 LAMEA Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%))
Figure 206 Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 207 Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 208 Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 209 Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 210 Brazil Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 211 South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 212 South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 213 South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 214 South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 215 South Africa Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 216 Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 217 Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 218 Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 219 Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 220 Saudi Arabia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 221 Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 222 Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 223 Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 224 Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 225 Turkey Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 226 UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 227 UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 228 UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 229 UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 230 UAE Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 231 Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 232 Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 233 Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 234 Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 235 Rest of LAMEA Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 234 Pfizer Inc.: Company Operating Income 2017-2021 (US$Mn, AGR %)
Figure 235 Pfizer Inc.: Company Net Income 2017-2021 (US$Mn, AGR %)
Figure 236 Pfizer Inc.: Company EBITDA 2017-2021 (US$Mn, AGR %)
Figure 237 Novartis AG: Company Revenue 2017-2021 (US$Mn, AGR %)
Figure 238 Novartis AG: Company Operating Income 2017-2021 (US$Mn, AGR %)
Figure 239 Novartis AG : Company Net Income 2017-2021 (US$Mn, AGR %)
Figure 240 Novartis AG : Company EBITDA 2017-2021 (US$Mn, AGR %)
Figure 241 Boehringer Ingelheim GmbH: Company Revenue 2017-2021 (US$Mn, AGR %)
Figure 242 Amgen Inc: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 243 Amgen Inc: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 244 Amgen Inc: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 245 Biocon Limited: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 246 Biocon Limited: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 247 Biocon Limited: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 248 Biocon Limited: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 249 Celltrion Healthcare Co Ltd: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 250 Celltrion Healthcare Co Ltd: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 251 Celltrion Healthcare Co Ltd: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 252 Celltrion Healthcare Co Ltd: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 253 Dong-A Socio Holdings Co., Ltd: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 254 Dong-A Socio Holdings Co., Ltd: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 255 Dong-A Socio Holdings Co., Ltd: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 256 Dong-A Socio Holdings Co., Ltd: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 257 Dr. Reddy’s Laboratories Limited: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 258 Dr. Reddy’s Laboratories Limited: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 259 Dr. Reddy’s Laboratories Limited: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 260 Dr. Reddy’s Laboratories Limited: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 261 3SBio Inc: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 262 3SBio Inc: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 263 3SBio Inc: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 264 3SBio Inc: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 265 AbbVie Inc: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 266 AbbVie Inc: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 267 AbbVie Inc: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 268 AbbVie Inc: Company EBITDA 2017-2021(US$Mn, AGR %)
Figure 269 Torrent Pharmaceuticals Limited: Company Revenue 2017-2021(US$Mn, AGR %)
Figure 270 Torrent Pharmaceuticals Limited: Company Operating Income 2017-2021(US$Mn, AGR %)
Figure 271 Torrent Pharmaceuticals Limited: Company Net Income 2017-2021(US$Mn, AGR %)
Figure 272 Torrent Pharmaceuticals Limited: Company EBITDA 2017-2021(US$Mn, AGR %)

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

Visiongain 社の最新刊レポート

本レポートと同じKEY WORD（biosimilar）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。